We use necessary cookies to make our website work. We also use optional statistical, functional and marketing cookies that you can choose to decline in your preference setting. For more information about the use of cookies or our use of data, see our Cookies notice or Privacy notice

Cookies settings I agree I disagree

Cookies information

Our site uses tools, such as cookies, to analyze and improve your experience. You can unsubscribe below:

Statistic

We use tools such as Google Analytics to track web traffic and check the effectiveness of our site.

Necessary

Cookies required for essential services and features such as login forms, shopping cart integration and access control. Without them, our website cannot function properly and we cannot provide any services. Deactivation is not available.

These settings will be kept for 24h

Publications

A Tick Molecule to Rescue Lives after Intracerebral Hemorrhage

A Tick Molecule to Rescue Lives after Intracerebral Hemorrhage
Publications
A Tick Molecule to Rescue Lives after Intracerebral Hemorrhage

Stéphanie DemoulinA, Valérie PireauxA, Marc DechampsA, Hans WarrinnierA, Edmond GodfroidA

  • A
    Gosselies, Belgium

Documents

Poster

Introduction

Imagine a world where a stroke - specifically an intracerebral haemorrhage (ICH) – has less devastating effects than now. In ICH, the initial bleeding in the brain triggers inflammation and blood clots that often worsen the damage for a patient. Bioxodes is developing a treatment – called BIOX-101 – that targets these secondary effects, and may help the recovery outcome. The active ingredient stems from an unexpected source: ticks. These tiny creatures, widely condemned as a disease-carrying pest, have a good side too: their saliva contains molecules that researchers have transformed into a potential game-changer in stroke treatment.

The study

To study BIOX-101's efficacy, we conducted trials on mice with induced ICH. We divided these into groups, some receiving BIOX-101, others a placebo, and yet others a standard treatment. We then monitored brain health using imaging techniques.

Key findings

We found that BIOX-101 did not worsen brain swelling or bleeding compared to the placebo. Importantly, it reduced harmful inflammation, and protected neuronal cells from damage. This is crucial because current treatments can sometimes increase swelling and bleeding without effectively targeting the cause of inflammation.

Potential impact

The findings were especially exciting because there is a significant need for better treatments for ICH. Each year, more than 3 million people worldwide experience ICH, resulting in 2.8 million deaths. What's even more concerning is that a large portion (68 %) of these cases occur in people under 70 years old.

Conclusion

BIOX-101 could be a game-changer in stroke treatment. By targeting the inflammation and blood clot formation that follow brain bleeding, it has the potential to reduce mortality rates and improve recovery outcomes for patients. Bioxodes is currently running a Phase 2a trial in Belgium with ICH patients to test BIOX-101, offering a breakthrough hope for millions of patients around the world.